Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piclidenoson in Lowe syndrome
2026-525495-26-00Phase 2Authorised
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of piclidenoson in Lowe syndrome, sponsored by Can-Fite BioPharma Ltd. Primary endpoint: Improvement in renal uptake of 99mTc-DMSA after 6 months versus baseline. Planned start Oct 2026; status: authorised.
02
Drugs
piclidenoson
03
Conditions
Lowe syndrome
Beyond the preview
Go deeper on 2026-525495-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525495-26-00.